Caribou Biosciences Ownership | Who Owns Caribou Biosciences?
Caribou Biosciences Ownership Summary
Caribou Biosciences is owned by 54.22% institutional investors, 9.83% insiders, and 35.95% retail investors. Blackrock is the largest institutional shareholder, holding 7.78% of CRBU shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.91% of its assets in Caribou Biosciences shares.
CRBU Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Caribou Biosciences | 54.22% | 9.83% | 35.95% |
| Sector | Healthcare Stocks | 279.42% | 10.64% | -190.05% |
| Industry | Biotech Stocks | 64.05% | 10.69% | 25.27% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock | 6.95M | 7.78% | $11.39M |
| Blackrock funding, inc. /de | 6.56M | 7.26% | $10.44M |
| Pfizer | 4.69M | 5.19% | $7.46M |
| Vanguard group | 4.57M | 5.05% | $7.26M |
| Bank of america corp /de/ | 4.16M | 4.66% | $6.83M |
| Pfm health sciences, lp | 3.88M | 4.29% | $6.16M |
| Jpmorgan chase | 2.50M | 2.76% | $3.97M |
| Kynam capital management, lp | 2.41M | 2.66% | $3.83M |
| Schonfeld strategic advisors | 2.11M | 2.34% | $3.36M |
| Geode capital management | 1.97M | 2.18% | $3.14M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| 72 investment | 474.07K | 1.53% | $753.77K |
| Pfm health sciences, lp | 3.88M | 0.38% | $6.16M |
| Pfizer | 4.69M | 0.29% | $7.46M |
| Pale fire capital se | 734.20K | 0.26% | $1.17M |
| Green alpha advisors | 181.05K | 0.23% | $287.88K |
| Kynam capital management, lp | 2.41M | 0.23% | $3.83M |
| Bruce | 250.00K | 0.13% | $397.50K |
| Milestone asset management | 163.79K | 0.06% | $260.43K |
| Schonfeld strategic advisors | 2.11M | 0.02% | $3.36M |
| Maverick capital | 652.54K | 0.02% | $1.04M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Pfizer | 4.69M | 0.29% | 4.69M |
| Bank of america corp /de/ | 4.16M | 0.00% | 3.05M |
| Jpmorgan chase | 2.50M | 0.00% | 2.06M |
| Schonfeld strategic advisors | 2.11M | 0.02% | 467.74K |
| Two sigma advisers, lp | 1.47M | 0.01% | 416.60K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Avidity partners management lp | - | - | -5.79M |
| Alkeon capital management | - | - | -2.74M |
| Paradigm biocapital advisors lp | - | - | -2.17M |
| Point72 asset management | 1.02M | 0.00% | -1.11M |
| Fil | - | - | -860.67K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Pfizer | 4.69M | 0.29% | 4.69M | $7.46M |
| Ameriprise financial | 408.06K | 0.00% | 408.06K | $648.81K |
| Susquehanna fundamental investments | 180.82K | 0.00% | 180.82K | $287.51K |
| Sei investments | 64.36K | 0.00% | 64.36K | $102.34K |
| Keystone financial group | 45.40K | 0.01% | 45.40K | $72.19K |
Sold Out
| Holder | Change |
|---|---|
| Nbc securities | -2.00 |
| Nelson, van denburg & campbell wealth management group | -17.00 |
| Point72 asia (singapore) pte. | -19.00 |
| Frazier financial advisors | -40.00 |
| Daiwa securities group | -176.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | 133 | -1.48% | 50,255,248 | -13.75% | 54 | 1.31% | 54 | -28.00% | 44 | 62.96% |
| Dec 31, 2024 | 133 | 2.31% | 58,115,660 | 10.96% | 64 | 1.92% | 73 | 21.67% | 27 | -15.63% |
| Sep 30, 2024 | 130 | -6.47% | 52,373,357 | -1.44% | 57 | 1.64% | 61 | -8.96% | 33 | -19.51% |
| Jun 30, 2024 | 139 | -10.32% | 53,138,330 | -20.38% | 59 | 1.04% | 67 | -8.22% | 41 | -6.82% |
| Mar 31, 2024 | 155 | 6.90% | 66,737,162 | -3.26% | 75 | 1.11% | 73 | -10.98% | 44 | 33.33% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.70M | 2.91% | - |
| ACATIS Datini Valueflex Fonds A | 2.00M | 2.15% | - |
| Selectra J. Lamarck Biotech A | 1.50M | 1.61% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.23M | 1.32% | - |
| abrdn Life Sciences Investors | 897.58K | 0.97% | - |
| Fidelity Small Cap Index | 843.92K | 0.91% | - |
| JPMorgan US Small Company L | 786.21K | 0.87% | -22.84K |
| iShares Russell 2000 Value ETF | 762.12K | 0.82% | - |
| Candriam Global Equities Oncology | 625.00K | 0.69% | -520.00K |
| iShares Biotechnology ETF | 556.11K | 0.61% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 14, 2025 | Haurwitz Rachel E. | President and CEO | Buy | $20.40K |
| Feb 21, 2025 | MCCLUNG BARBARA G | Chief Legal Officer | Sell | $4.81K |
| Feb 21, 2025 | Khan Ruhi Ahmad | Chief Business Officer | Sell | $4.81K |
| Feb 21, 2025 | Kanner Steven | Chief Scientific Officer | Sell | $4.81K |
| Jan 29, 2025 | Ryali Sriram | Chief Financial Officer | Buy | $24.65K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | 1 | 3 |
| 2024 Q4 | - | - |
| 2024 Q3 | - | - |
| 2024 Q1 | - | - |
| 2023 Q2 | - | - |
CRBU Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools